Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity

B Zingales - Acta tropica, 2018 - Elsevier
The genetic diversity of Trypanosoma cruzi, the protozoan agent of Chagas disease, is
widely recognized. At present, T. cruzi is partitioned into seven discrete typing units (DTUs) …

[HTML][HTML] Advances in the treatment of Chagas disease: Promising new drugs, plants and targets

P García-Huertas, N Cardona-Castro - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs;
benznidazole and nifurtimox. These drugs have some disadvantages, including their …

Current drug therapy and pharmaceutical challenges for Chagas disease

J Bermudez, C Davies, A Simonazzi, JP Real, S Palma - Acta tropica, 2016 - Elsevier
One of the most significant health problems in the American continent in terms of human
health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite …

Review on Experimental Treatment Strategies Against Trypanosoma cruzi

AL Mazzeti, P Capelari-Oliveira, MT Bahia… - Journal of …, 2021 - Taylor & Francis
Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma
cruzi. Currently, only nitroheterocyclic nifurtimox (NFX) and benznidazole (BNZ) are …

The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets

F Altamura, R Rajesh, CMC Catta‐Preta… - Drug development …, 2022 - Wiley Online Library
Human trypanosomiasis and leishmaniasis are vector‐borne neglected tropical diseases
caused by infection with the protozoan parasites Trypanosoma spp. and Leishmania spp …

Chagas disease diagnostic applications: present knowledge and future steps

V Balouz, F Agüero, CA Buscaglia - Advances in parasitology, 2017 - Elsevier
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating
illness of major significance throughout Latin America and an emergent threat to global …

[HTML][HTML] Fexinidazole: a potential new drug candidate for Chagas disease

MT Bahia, IM Andrade, TAF Martins… - PLoS neglected …, 2012 - journals.plos.org
Background New safe and effective treatments for Chagas disease (CD) are urgently
needed. Current chemotherapy options for CD have significant limitations, including failure …

[HTML][HTML] Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery

LM MacLean, J Thomas, MD Lewis… - PLoS neglected …, 2018 - journals.plos.org
Chagas' disease is responsible for significant mortality and morbidity in Latin America.
Current treatments display variable efficacy and have adverse side effects, hence more …

[HTML][HTML] Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments

LF Diniz, JA Urbina, IM de Andrade… - PLoS neglected …, 2013 - journals.plos.org
Background Current chemotherapy for Chagas disease is unsatisfactory due to its limited
efficacy, particularly in the chronic phase, with frequent side effects that can lead to treatment …

Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi

E Izumi, T Ueda-Nakamura, BP Dias Filho… - Natural Product …, 2011 - pubs.rsc.org
Covering: 1995 to 2010 Here, we review studies that have investigated the activity of plant-
derived compounds against Trypanosoma cruzi, the etiologic agent of Chagas' disease. In …